Sanofi News | finanzen.ch

Kurse + Charts + Realtime	News + Analysen	Fundamental	Unternehmen	zugeh. Wertpapiere	Aktion
Kurs + Chart	Chart (gross)	News + Adhoc	Bilanz/GuV	Termine	Strukturierte Produkte	Portfolio
Times + Sales	Chartvergleich	Analysen	Schätzungen	Profil		Watchlist
Börsenplätze	Realtime Push	Kursziele	Dividende/GV
Orderbuch			Analysen
Historisch

Kurse + Charts + Realtime

News + Analysen

Fundamental

Unternehmen

zugeh. Wertpapiere

Aktion

Kurs + Chart

Chart (gross)

News + Adhoc

Bilanz/GuV

Termine

Strukturierte Produkte

Portfolio

Times + Sales

Chartvergleich

Analysen

Schätzungen

Profil

Watchlist

Börsenplätze

Realtime Push

Kursziele

Dividende/GV

Orderbuch

Analysen

Historisch

12.09.18	Sanofi And Regeneron : FDA To Review SBLA For Praluent Injection (RTTNews)
12.09.18	FOMX Soars On Acne Trial Data, GLPG Abuzz, ACRX To Face FDA Panel In Oct. (RTTNews)
12.09.18	FDA to review supplemental Biologics License Application for Praluent® (alirocumab) Injection as potential treatment to reduce major adverse cardiovascular events (GlobeNewswire)
05.09.18	SEC : Sanofi Agrees To Pay More Than $25 Mln To Settle Corruption Charges (RTTNews)
04.09.18	Sanofi reaches civil settlement with US SEC (GlobeNewswire)
03.09.18	Sanofi: EC Grants Marketing Authorization For Cablivi To Treat ATTP (RTTNews)
03.09.18	Sanofi: Cablivi(TM) (caplacizumab) approved in Europe for adults with acquired thrombotic thrombocytopenic purpura (aTTP) (GlobeNewswire)
09.08.18	This Day That Year: Zealand Pharma (RTTNews)
31.07.18	Online Availability of Sanofi Group's Half-Year Financial Report for 2018 (GlobeNewswire)
31.07.18	Sanofi Q2 Profit Down 26%; Narrows FY18 Business EPS View - Quick Facts (RTTNews)
26.07.18	Sanofi Head of Human Resources Roberto Pucci to retire; Company names Caroline Luscombe to take over October 1st (GlobeNewswire)
29.06.18	Sanofi: Availability of the Pre-quarterly Results Communication (GlobeNewswire)
29.06.18	Sanofi: CHMP Recommends Approval Of Cablivi For Rare Blood Disorder (RTTNews)
29.06.18	Sanofi: CHMP recommends approval of Cablivi(TM) (caplacizumab) (GlobeNewswire)
25.06.18	Sanofi Reports Positive Results From Study Comparing Insulin Toujeo To Degludec (RTTNews)
25.06.18	Evotec Gets EUR 3 Mln Beta Cell Therapy Milestone Payment From Sanofi (RTTNews)
22.06.18	NICE Recommends Sanofi's New Treatment Dupixent(R) ▼ (dupilumab) for Adults with Moderate to Severe Atopic Dermatitis in England[1] (PR Newswire)
19.06.18	Sanofi appoints Jean-Baptiste Chasseloup de Chatillon Executive Vice President, Chief Financial Officer (GlobeNewswire)
19.06.18	Sanofi Closes Acquisition Of Ablynx (RTTNews)
19.06.18	Sanofi : Sanofi completes its acquisition of Ablynx following the expiration of the Squeeze-out Procedure (GlobeNewswire)
13.06.18	Sanofi : Sanofi successfully prices USD 2 billion bond issue (GlobeNewswire)
11.06.18	Translate Bio, Sanofi Pasteur Join To Advance MRNA Vaccines - Quick Facts (RTTNews)
11.06.18	Sanofi Launches "Action 2018", a Worldwide Employee Stock Purchase Plan (GlobeNewswire)
04.06.18	Sanofi: New England Journal of Medicine publishes pivotal cemiplimab trials showing positive results in advanced cutaneous squamous cell carcinoma (GlobeNewswire)
22.05.18	Lexicon Pharma: FDA To Review Sanofi's Filing For Zynquista - Quick Facts (RTTNews)
21.05.18	Sanofi: New England Journal of Medicine publishes two positive Phase 3 trials showing Dupixent® (dupilumab) improved moderate-to-severe asthma (GlobeNewswire)
16.05.18	Regeneron, Sanofi: Phase 3 Dupixent Trial Meets Primary, Key Secondary Endpoints (RTTNews)
16.05.18	Sanofi: Dupixent® (dupilumab) showed positive Phase 3 results in adolescents with inadequately controlled moderate-to-severe atopic dermatitis (GlobeNewswire)
14.05.18	Sanofi and Ablynx Announce the Successful Results of the Initial Tender Offer Period for Ablynx and Commencement of Squeeze-Out Tender Period (GlobeNewswire)
14.05.18	Sanofi and Ablynx Announce the Successful Results of the Initial Tender Offer Period for Ablynx and Commencement of Squeeze-Out Tender Period (GlobeNewswire)
02.05.18	Sanofi: Annual General Shareholders' Meeting of May 2, 2018 (GlobeNewswire)
01.05.18	Sanofi, Renegeron To Lower Net Price Of Praluent Injection - Quick Facts (RTTNews)
01.05.18	INGN Soars On Revised Outlook, MRK Faces FDA In Sep., KPTI Taken By STORM (RTTNews)
30.04.18	Regeneron And Sanofi Say FDA Accepts Priority Review BLA For Cemiplimab (RTTNews)
30.04.18	Sanofi: FDA to Conduct Priority Review of Cemiplimab as a Potential Treatment for Advanced Cutaneous Squamous Cell Carcinoma (GlobeNewswire)
27.04.18	Sanofi Q1 Profit Drops; Backs 2018 Business EPS View (RTTNews)
24.04.18	Sanofi Names Roche's John Reed Head Of Global R&D, Succeeding Elias Zerhouni (RTTNews)
24.04.18	Sanofi Head of Global R&D Elias Zerhouni to retire; Company names John Reed to take over on July 1 (GlobeNewswire)
17.04.18	Advent International enters into exclusive negotiations to acquire Zentiva, Sanofi's European generics business (GlobeNewswire)
12.04.18	Sanofi to invest €350 million in Canadian vaccine facility (GlobeNewswire)
06.04.18	A Glance At Potential Therapies For Sickle Cell Disease (RTTNews)
05.04.18	Sanofi Announces Its Insulins VALyou Savings Program - Quick Facts (RTTNews)
03.04.18	Will These Drugs Reach Blockbuster Status? (RTTNews)
03.04.18	Regeneron And Sanofi Say EMA Accepts For Review Application For DUPIXEN (RTTNews)
03.04.18	Sanofi: EMA to review Dupixent® (dupilumab) as potential treatment for inadequately controlled moderate-to-severe asthma (GlobeNewswire)
03.04.18	Sanofi: EMA to review cemiplimab as a potential treatment for advanced cutaneous squamous cell carcinoma (GlobeNewswire)
29.03.18	Sanofi: EMA To Review Regulatory Submission For Sotagliflozin - Quick Facts (RTTNews)
29.03.18	Sanofi: EMA to review sotagliflozin as potential treatment for type 1 diabetes (GlobeNewswire)
29.03.18	Previously announced Tender Offers by Sanofi to acquire Ablynx will commence on April 4, 2018 (GlobeNewswire)
28.03.18	Sanofi: Availability of the Pre-quarterly Results Communication (GlobeNewswire)

Aktien Top/Flop

SMI
SPI
SLI
SMIM
DAX
ESTOXX
Dow Jones
S&P 500
NASDAQ 100
Nikkei 225

Part Grp Hldg	1’263.50	2.89 %	K V
Sonova Hldg	312.10	2.66 %	K V
Novartis	93.68	2.32 %	K V
Geberit	526.80	1.97 %	K V
Roche Hldg G	254.30	1.27 %	K V
Kuehne+Nagel Int	209.50	0.72 %	K V
UBS Group	28.30	0.57 %	K V
Givaudan	3’933.00	0.36 %	K V
Nestle	76.00	0.05 %	K V
Lonza Grp	521.40	-0.04 %	K V

mehr

22.11.24		Dow Jones aktuell: Dow Jones zum Ende des Freitagshandels in der Gewinnzone
22.11.24		S&P 500-Handel aktuell: S&P 500 liegt letztendlich im Plus
22.11.24		Freundlicher Handel: NASDAQ 100 verbucht zum Ende des Freitagshandels Zuschläge
22.11.24		Gute Stimmung in New York: nachmittags Pluszeichen im S&P 500
22.11.24		Gewinne in New York: NASDAQ 100 präsentiert sich fester
22.11.24		Freundlicher Handel in New York: Dow Jones präsentiert sich am Freitagnachmittag fester
22.11.24		Börse New York in Grün: Dow Jones bewegt sich am Mittag im Plus

22.11.24

Dow Jones aktuell: Dow Jones zum Ende des Freitagshandels in der Gewinnzone

22.11.24

S&P 500-Handel aktuell: S&P 500 liegt letztendlich im Plus

22.11.24

Freundlicher Handel: NASDAQ 100 verbucht zum Ende des Freitagshandels Zuschläge

22.11.24

Gute Stimmung in New York: nachmittags Pluszeichen im S&P 500

22.11.24

Gewinne in New York: NASDAQ 100 präsentiert sich fester

22.11.24

Freundlicher Handel in New York: Dow Jones präsentiert sich am Freitagnachmittag fester